Utilized for hiv-1 infection to manage viral replication and support immune system stability.
Mechanism of Action
Dolutegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step of viral DNA integration. This prevents the viral genome from integrating into the host cell DNA.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours
Contraindications
Concurrent use of dofetilide, Hypersensitivity to dolutegravir
Severe Adverse Events
Hepatotoxicity, Severe hypersensitivity, Immune reconstitution syndrome — requires immediate medical attention
Common Side Effects
Insomnia, Headache, Fatigue
Uncommon Side Effects
Nausea, Diarrhea, Rash
Drug Interactions
Alcohol, Antacids, Metformin, Rifampin, Phenytoin
Pregnancy Safety Warnings
FDA Category B: Safe for use during pregnancy. Breastfeeding: Not recommended for HIV-positive mothers.
Age Restrictions
Safety and efficacy established in pediatric patients weighing at least 3 kg.
Information related to Dolutegravir is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
